Sunday, 3 March 2024

Business News

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ – TipRanks Financial Blog

CSL Logo

Strong CSL Behring portfolio growth especially Ig


  • Revenue $8.05 billion, up 11% at CC3
  • NPAT $1.90 billion1, up 17%
  • NPAT $1.94 billion1 at CC3, up 20%
  • NPATA $2.02 billion1,2 , up 11%
  • NPATA $2.06 billion1,2 at CC3, up 13%
  • NPATA1,2 earnings per share $4.182, up 11%
    • NPATA1,2 earnings per share $4.26 at CC3 up 13%
  • Interim dividend 5 of US$1.19 per share
    • Converted to Australian currency, the interim dividend is approximately A$1.81 per share, up 12%
  • Guidance reaffirmed – FY24 NPATA2,4 anticipated to be in the range of approximately $2.9 billion to $3.0 billion2 at CC3 

MELBOURNE, Australia, Feb. 13, 2024 /PRNewswire/ — CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.

Dr. Paul McKenzie, CSL’s Chief Executive Officer and Managing Director said, “Our strong first-half result for the 2024 financial year was driven by CSL Behring’s exceptional performance across its portfolio, especially immunoglobulins.  The plasma initiatives we have implemented are starting to drive gross margin recovery.

“CSL Seqirus achieved solid growth in a challenging season.  Its portfolio of differentiated products outperformed the market.

“For CSL Vifor we are well prepared for the transitioning iron market.”  


CSL Behring

Total revenue was $5,238 million, up 14%3 when compared to the prior comparable period.

Immunoglobulin (Ig) product sales of $2,757 million, increased 23%3 with strong growth recorded across all geographies driven by global plasma supply and patient demand.

PRIVIGEN®  / INTRAGRAM® (Immune Globulin Intravenous (Human), 10% Liquid) sales grew 27%3 as the momentum from the prior year continued in improving product availability and patient diagnosis rates.

HIZENTRA® (Immune Globulin Subcutaneous (Human), 20% Liquid) sales were up 18%3 driven by  patient diagnosis rates.  HIZENTRA® continues to be the clear market leader for subcutaneous immunoglobulin.

Underlying demand for Ig continues to be strong due to significant patient needs in core indications – namely Primary Immune Deficiency, Secondary Immune Deficiency and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Albumin sales of $613 million, were up…

Click Here to Read the Full Original Article at TipRanks Financial Blog…